Galectin-3 in acute coronary syndrome

被引:68
作者
Agnello, Luisa [1 ]
Bivona, Giulia [1 ]
Lo Sasso, Bruna [1 ]
Scazzone, Concetta [1 ]
Bazan, Viviana [2 ]
Bellia, Chiara [1 ]
Ciaccio, Marcello [1 ,3 ]
机构
[1] Univ Palermo, Dipartimento Biopatol & Biotecnol Med, Sez Biochim Clin & Med Mol Clin, Palermo, Italy
[2] Univ Palermo, Dipartimento Discipline Chirurg Oncol & Stomatol, Palermo, Italy
[3] AOUP P Giaccone, CoreLab, UOC Med Lab, Palermo, Italy
关键词
Galectin-3; Acute coronary syndrome; Myocardial infarction; AMI; Prognosis; Heart failure; 2013 ACCF/AHA GUIDELINE; ASSOCIATION TASK-FORCE; MYOCARDIAL-INFARCTION; HEART-FAILURE; ARTERY-DISEASE; INHIBITION; EXPRESSION; MARKER; INFLAMMATION; DYSFUNCTION;
D O I
10.1016/j.clinbiochem.2017.04.018
中图分类号
R446 [实验室诊断]; R-33 [实验医学、医学实验];
学科分类号
1001 ;
摘要
Acute coronary syndrome (ACS) is a very common cause of hospitalizations worldwide each year. In the past decades biomarkers have become an indispensable tool for diagnosis, risk stratification and prognosis of cardiovascular disease, including ACS. Despite Troponin is considered the gold standard in diagnosis of ACS, several molecules have been investigated to identify predictive biomarkers of prognosis. Among these, Gal-3 has emerged as a promising prognostic marker. It has a pivotal role in inflammation and fibrosis. Both experimental and clinical studies have shown Gal-3 is an independent predictor of all-cause mortality, cardiovascular death and occurrence of HF following ACS. This article reviews the literature data regarding the role of Galectin-3 in ACS setting.
引用
收藏
页码:797 / 803
页数:7
相关论文
共 64 条
[1]   Is galectin-3 a biomarker, a player-or both-in the presence of coronary atherosclerosis? [J].
Aksan, Gokhan ;
Gedikli, Omer ;
Keskin, Kudret ;
Nar, Gokay ;
Inci, Sinan ;
Yildiz, Suleyman Sezai ;
Kaplan, Ozgur ;
Soylu, Korhan ;
Kilickesmez, Kadriye Orta ;
Sahin, Mahmut .
JOURNAL OF INVESTIGATIVE MEDICINE, 2016, 64 (03) :764-770
[2]   Galectin-3 and Plasma Cytokines in Patients With Acute Myocardial Infarction [J].
Alturfan, A. Ata ;
Basar, Isik ;
Emekli-Alturfan, Ebru ;
Ayan, Faruk ;
Koldas, Lale ;
Emekli, Nesrin .
LABMEDICINE, 2014, 45 (04) :332-337
[3]  
[Anonymous], ARTERIOSCLER THROMB
[4]  
[Anonymous], ARCH MED RE IN PRESS
[5]  
[Anonymous], HEART
[6]   Local expression of myocardial galectin-3 does not correlate with its serum levels in patients undergoing heart transplantation [J].
Beiras-Fernandez, Andres ;
Weis, Florian ;
Rothkopf, Julia ;
Kaczmarek, Ingo ;
Ledderose, Carola ;
Dick, Andrea ;
Keller, Till ;
Beiras, Andres ;
Kreth, Simone .
ANNALS OF TRANSPLANTATION, 2013, 18 :643-650
[7]   Mineralocorticoid Receptor Antagonist Pretreatment to MINIMISE Reperfusion Injury After ST-Elevation Myocardial Infarction (The MINIMISE STEMI Trial): Rationale and Study Design [J].
Bulluck, Heerajnarain ;
Froehlich, Georg M. ;
Mohdnazri, Shah ;
Gamma, Reto A. ;
Davies, John R. ;
Clesham, Gerald J. ;
Sayer, Jeremy W. ;
Aggarwal, Rajesh K. ;
Tang, Kare H. ;
Kelly, Paul A. ;
Jagathesan, Rohan ;
Kabir, Alamgir ;
Robinson, Nicholas M. ;
Sirker, Alex ;
Mathur, Anthony ;
Blackman, Daniel J. ;
Ariti, Cono ;
Krishnamurthy, Arvindra ;
White, Steven K. ;
Meier, Pascal ;
Moon, James C. ;
Greenwood, John P. ;
Hausenloy, Derek J. .
CLINICAL CARDIOLOGY, 2015, 38 (05) :259-266
[8]   Galectin-3 Mediates Aldosterone-Induced Vascular Fibrosis [J].
Calvier, Laurent ;
Miana, Maria ;
Reboul, Pascal ;
Cachofeiro, Victoria ;
Martinez-Martinez, Ernesto ;
de Boer, Rudolf A. ;
Poirier, Francoise ;
Lacolley, Patrick ;
Zannad, Faiez ;
Rossignol, Patrick ;
Lopez-Andres, Natalia .
ARTERIOSCLEROSIS THROMBOSIS AND VASCULAR BIOLOGY, 2013, 33 (01) :67-+
[9]   Macrophage phenotypes in atherosclerosis [J].
Colin, Sophie ;
Chinetti-Gbaguidi, Giulia ;
Staels, Bart .
IMMUNOLOGICAL REVIEWS, 2014, 262 (01) :153-166
[10]   Galectin-3 expression in response to LPS, immunomodulatory drugs and exogenously added galectin-3 in monocyte-like THP-1 cells [J].
Dabelic, Sanja ;
Novak, Ruder ;
Goreta, Sandra Supraha ;
Dumic, Jerka .
IN VITRO CELLULAR & DEVELOPMENTAL BIOLOGY-ANIMAL, 2012, 48 (08) :518-527